Drugs / MVX-220
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07181837 | Oct 2025 → Mar 2028 expected | Angelman syndrome | MavriX Bio, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVX-220 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07181837 ↗ |
| Action | Restore | “MVX-220 is an investigational gene replacement therapy intended to provide a functional copy of the UBE3A gene” NCT07181837 ↗ |
| Route | Other | “single dose intra cisterna magna injection” NCT07181837 ↗ |
| Target | UBE3A | “functional copy of the UBE3A gene” NCT07181837 ↗ |